DK9197A - Vaccine baseret på membranbundne proteiner og fremgangsmåde til fremstilling deraf - Google Patents

Vaccine baseret på membranbundne proteiner og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK9197A
DK9197A DK009197A DK9197A DK9197A DK 9197 A DK9197 A DK 9197A DK 009197 A DK009197 A DK 009197A DK 9197 A DK9197 A DK 9197A DK 9197 A DK9197 A DK 9197A
Authority
DK
Denmark
Prior art keywords
membrane
preparation
bound proteins
vaccine based
vaccine
Prior art date
Application number
DK009197A
Other languages
English (en)
Inventor
Phillip Wayne Berman
Laurence Allan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK9197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK9197A publication Critical patent/DK9197A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK009197A 1983-08-30 1997-01-24 Vaccine baseret på membranbundne proteiner og fremgangsmåde til fremstilling deraf DK9197A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52791783A 1983-08-30 1983-08-30
US54755183A 1983-10-31 1983-10-31
US58817084A 1984-03-09 1984-03-09

Publications (1)

Publication Number Publication Date
DK9197A true DK9197A (da) 1997-01-24

Family

ID=27414978

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198404122A DK172694B1 (da) 1983-08-30 1984-08-29 Vacciner indeholdende glycoprotein C eller D fra herpes simplex virus
DK009197A DK9197A (da) 1983-08-30 1997-01-24 Vaccine baseret på membranbundne proteiner og fremgangsmåde til fremstilling deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198404122A DK172694B1 (da) 1983-08-30 1984-08-29 Vacciner indeholdende glycoprotein C eller D fra herpes simplex virus

Country Status (13)

Country Link
US (1) US5851533A (da)
EP (1) EP0139417B2 (da)
JP (2) JP2599350B2 (da)
AU (1) AU579323B2 (da)
CA (1) CA1341181C (da)
DE (1) DE3479085D1 (da)
DK (2) DK172694B1 (da)
ES (2) ES8605039A1 (da)
GR (1) GR80220B (da)
HK (1) HK98792A (da)
IE (1) IE58030B1 (da)
IL (1) IL72785A (da)
NZ (1) NZ209308A (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
GR862472B (en) * 1986-09-30 1986-10-09 Elliniko Institouto Paster Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
AU6161390A (en) * 1989-07-31 1991-03-11 Basil Rapaport Recombinant human thyroid peroxidase
CA2088600C (en) * 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
JPH07506960A (ja) * 1991-08-28 1995-08-03 ニコルス・インスティチュート・ダイアグノスティクス ヒト甲状腺ペルオキシダーゼに特異的な疾病関連性ヒト抗体
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20020090382A1 (en) * 2000-08-01 2002-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds and methods
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
EP2289547B1 (en) 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2006058000A1 (en) 2004-11-24 2006-06-01 Shell Internationale Research Maatschappij B.V. Separator for multi-phase slug flow and method of designing same
CN101583381B (zh) 2006-09-08 2014-05-07 宾夕法尼亚大学董事会 Hsv-1和hsv-2疫苗和其使用方法
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
AU2007342345B9 (en) * 2006-12-28 2013-09-12 The Trustees Of The University Of Pennsylvania Herpes Simplex Virus combined subunit vaccines and methods of use thereof
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DK2343052T3 (da) 2009-12-03 2013-09-02 Novartis Ag Hydrofil filtrering under fremstilling af vaccineadjuvanter
EP2506834B1 (en) 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PL2380558T5 (pl) 2009-12-03 2020-10-05 Novartis Ag Wytwarzanie emulsji w układzie komory oddziaływań i komory przeciwciśnieniowej do mikrofluidyzacji
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2011251706B2 (en) 2010-05-12 2015-10-22 Seqirus UK Limited Improved methods for preparing squalene
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
WO2015134368A2 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
WO2016087479A1 (en) 2014-12-02 2016-06-09 Novartis Ag Manufacture of surfactant-containing compositions
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
AU2021302954A1 (en) 2020-06-30 2023-02-16 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
AU559550B2 (en) * 1981-03-09 1987-03-12 Cetus Corporation Vaccines
GB2103622B (en) 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
DE3461928D1 (en) * 1983-06-23 1987-02-12 Person Stanley Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
ATE230798T1 (de) * 1984-04-06 2003-01-15 Chiron Corp Rekombinanter herpes simplex gb-gd-impfstoff
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
DE3582200D1 (de) * 1984-07-20 1991-04-25 Chemo Sero Therapeut Res Inst Rekombinante dns, enthaltend ein herpes-simplex-virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex-virus-proteinen.

Also Published As

Publication number Publication date
DK412284D0 (da) 1984-08-29
EP0139417B1 (en) 1989-07-26
DE3479085D1 (en) 1989-08-31
HK98792A (en) 1992-12-18
ES8605039A1 (es) 1986-03-16
US5851533A (en) 1998-12-22
ES8705036A1 (es) 1987-05-01
EP0139417A1 (en) 1985-05-02
JP2599350B2 (ja) 1997-04-09
AU579323B2 (en) 1988-11-24
IL72785A (en) 1990-07-26
GR80220B (en) 1984-11-15
DK412284A (da) 1985-04-11
IE58030B1 (en) 1993-06-16
JPS60155128A (ja) 1985-08-15
CA1341181C (en) 2001-02-20
ES535554A0 (es) 1986-03-16
JPH08253428A (ja) 1996-10-01
IE842210L (en) 1985-02-28
DK172694B1 (da) 1999-05-31
AU3242384A (en) 1985-03-07
EP0139417B2 (en) 1999-03-17
IL72785A0 (en) 1984-11-30
ES552539A0 (es) 1987-05-01
NZ209308A (en) 1991-08-27

Similar Documents

Publication Publication Date Title
DK412284D0 (da) Vacciner baseret paa membran-bundne proteiner og fremgangsmaade til fremstilling deraf
DK166087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
DK261782A (da) Overfladebehandlingsmetode og praeparat til cement
DK491483D0 (da) Ophthalmisk praeparat og fremgangsmade til fremstilling heraf
DK256485A (da) Veterinaert praeparat og fremgangsmaade til fremstilling deraf
DK559387D0 (da) Fremgangsmaade og mellemprodukt til fremstilling af 3-pyrrolidinoler
DK164843C (da) Theophyllin-retardpraeparat og fremgangsmaade til fremstilling heraf
DK314786A (da) Fremgangsmaade til fremstilling af proteiner og polypeptider
DK204884A (da) Gaerudtrykkelsesmedium, gaerorganisme transformeret dermed og fremgangsmaade til fremstilling af et for gaer heterologt protein
DK437386A (da) Undersoegelsesmetode til afsloering af antistoffer over for retrovira og undersoegelsessaet til ansendelse herved
DK203087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
DK621484D0 (da) Acylaminomitosaner og fremgangsmaade til fremstilling deraf
DK379885A (da) Antibiotica og fremgangsmaade til fremstilling heraf
DK67786A (da) Fremgangsmaade til fremstilling af arylglycidylethere og 3-substituerede 1-alkylamino-2-propanoler
DK326082A (da) Heptadecapeptid og fremgangsmaade til fremstilling heraf
DK434984A (da) Antibiotisk forbindelse og fremgangsmaade til fremstilling heraf
DK26384A (da) Toxoplasmosefaktor og fremgangsmaade til fremstilling deraf
DK552284D0 (da) 2-chlor-3-trifluormethylbenzaldehyd og fremgangsmaade til fremstilling deraf
DK382284D0 (da) Fremgangsmaade til fremstilling af 7-acylamino-3-hydroxy-cephem-4-carbxylsyrer og 7-acylamino-3-hydroxy-1-dethia-1-oxacephem-4-carboxylsrer
DK102785D0 (da) Termostabil pollulanase og fremgangsmaade til fremstilling deraf
DK296984A (da) 3-substituerede-3-aminonitriler og fremgangsmaade til deres fremstilling
DK50686D0 (da) Difficolforbindelse og fremgangsmaade til fremstilling deraf
DK284184D0 (da) 1-phenoxy-3-hydroxyindolylalkylamino-3-propanoler og fremgangsmaade til fremstilling deraf
DK560086D0 (da) Bjaelke og fremgangsmaade til fremstilling af samme
DK372885D0 (da) Vaccine og fremgangsmaade til fremstilling heraf

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment